Enanta Pharmaceuticals Inc
ENTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001177648
No open-market purchases or sales by Enanta Pharmaceuticals Inc insiders were filed in the last 90 days; 122 institutions reported holding it in 13F filings for Q2 2026, worth $397.2M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −7 vs. previous quarter
- 122
- 13F valueReported value at the end of Q2 2026
- $397.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ENTA, Q2 2026
No superinvestor reported holding ENTA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Enanta Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 5, 2025 (view filing) | Dec 5 | Same day | Capps Kathleen S.See Remarks | SSale | −323 | $14.23 | −$4.60K | −3.7%8.38K after | |
| Dec 5, 2025 (view filing) | Dec 5 | Same day | Trout Harry R. IIISee Remarks | SSale | −542 | $14.23 | −$7.71K | −3.2%16.3K after | |
| Dec 5, 2025 (view filing) | Dec 5 | Same day | Rottinghaus Scott T.Chief Medical Officer | SSale | −798 | $14.23 | −$11.4K | −3.5%21.8K after | |
| Dec 5, 2025 (view filing) | Dec 5 | Same day | Luu BrendanChief Business Officer | SSale | −1.39K | $14.23 | −$19.8K | −3.5%38.3K after | |
| Dec 5, 2025 (view filing) | Dec 5 | Same day | Kieffer Tara LynnChief Product Strategy Officer | SSale | −2.11K | $14.23 | −$30.0K | −6.4%30.6K after | |
| Dec 5, 2025 (view filing) | Dec 5 | Same day | Or Yat SunChief Scientific Officer | SSale | −2.39K | $14.23 | −$34.0K | −0.6%371.4K after | |
| Dec 5, 2025 (view filing) | Dec 5 | Same day | Luly Jay R.President and CEO | SSale | −4.74K | $14.23 | −$67.5K | −0.5%858.0K after | |
| Dec 3, 2025 (view filing) | Dec 2 | 1 day | Capps Kathleen S.See Remarks | SSale | −207 | $13.96 | −$2.89K | −2.3%8.70K after | |
| Dec 3, 2025 (view filing) | Dec 2 | 1 day | Trout Harry R. IIISee Remarks | SSale | −380 | $13.96 | −$5.30K | −2.2%16.9K after | |
| Feb 12, 2025 (view filing) | Feb 12 | Same day | Luly Jay R.President and CEO | PPurchase | +45.0K | $5.69 | +$256.1K | +5.6%846.6K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Enanta Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 3,654,920 | $53.3M | 0.02% | +3,654,920 | New |
| BlackRock, Inc. | 3,244,448 | $47.3M | 0.00% | +140,680+4.5% | Added |
| Krensavage Asset Management, LLC | 2,866,138 | $41.8M | 15.88% | 00.0% | Unchanged |
| Farallon Capital Management, L.L.C. | 2,418,202 | $35.3M | 0.21% | −453,660−15.8% | Reduced |
| Deep Track Capital, LP | 1,444,167 | $21.1M | 0.31% | −512,700−26.2% | Reduced |
| ADAR1 Capital Management, LLC | 1,344,510 | $19.6M | 0.92% | +1,293,153+2,518.0% | Added |
| Vanguard Capital Management LLC | 1,211,769 | $17.7M | 0.00% | +33,720+2.9% | Added |
| Spruce Street Capital LP | 1,088,731 | $15.9M | 3.11% | +156,133+16.7% | Added |
| Acadian Asset Management LLC | 1,078,317 | $15.7M | 0.02% | +198,294+22.5% | Added |
| Vanguard Portfolio Management LLC | 1,011,494 | $14.7M | 0.00% | +62,590+6.6% | Added |